Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYCS pseudogene 22 (CYCSP22, HCP22) is a processed pseudogene in the human genome related to the cytochrome c, somatic (CYCS/HCS) gene. Pseudogenes like CYCSP22 are DNA sequences resembling functional genes but have lost their ability to encode a protein due to mutations, frameshifts, or truncations[2][3]. CYCSP22 is one of at least 49 cytochrome c pseudogenes (HCPs) in humans, most of which are neither transcribed nor translated, and are considered evolutionary remnants of gene duplication or retrotransposition events[2]. There is no scientific evidence establishing any functional RNA or protein product from CYCSP22, and it is not a pharmacological or biological target in therapeutics or diagnostic applications[1][3]. Occasionally, some pseudogenes have been implicated in gene regulation in other systems, but this is not established for CYCSP22[4].
None established. No drugs or chemical modulators are known to act via this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CYCS pseudogene 22 (CYCSP22).